Drugs / Tesamorelin
Tesamorelin
also known as
TH9507 · Egrifta · GHRH(1-44) · TESAMORELIN ACETATE · Tesamorelina · Tesamoreline · TH-9507 ACETATE
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | EGRIFTA | — | 2010-11-10 | fda.gov ↗ |
Trials 19
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-05-02 | Theratechnologies | Results Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV theratech.com ↗
The second presentation reports on a first-of-its-kind case series in which the combination of tesamorelin and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) therapy was highly effective in reducing both EVAF and obesity in a real-world setting. |
All press releases naming this drug 2 releases
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tesamorelin | “Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat” PMID 20554713 ↗ Jun 201019“before and after 10 weeks of treatment with low-dose tesamorelin (1 mg; GHRH analog) or placebo.” PMID 42382101 ↗ Jun 2026 “Subjects received tesamorelin, a GHRH(1-44) analog, 2 mg once daily, or placebo for 12 months.” PMID 23015655 ↗ Sep 2012 “Tesamorelin (GHRH) 2mg SC QD x 2 weeks” NCT00795210 ↗ “tesamorelin (Theratechnologies Inc)” PMID 23689947 ↗ Jul 2013 |
| Known as | Egrifta | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237026 ↗ |
| Known as | GHRH(1-44) | “tesamorelin (GHRH(1-44)) at a dose of 2 mg or identical placebo, sc, was given daily.” PMID 20554713 ↗ Jun 2010 |
| Known as | TESAMORELIN ACETATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237026 ↗ |
| Known as | Tesamorelina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237026 ↗ |
| Known as | Tesamoreline | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237026 ↗ |
| Known as | TH-9507 ACETATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1237026 ↗ |
| Known as | TH9507 | “Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat” PMID 20554713 ↗ Jun 2010 |
| Action | Activate | “Tesamorelin, a growth hormone releasing hormone agonist, reduces liver fat in HIV-infected individuals.” PMID 29031905 ↗ Oct 20171“Growth hormone-releasing hormone receptor agonist” CHEMBL1237026 ↗ |
| Modality | Peptide | “Growth Hormone Releasing Hormone (GHRH) analog tesamorelin” NCT03226821 ↗ |
| Route | Subcutaneous | “tesamorelin [2 mg subcutaneous (SC) every day] or placebo” PMID 20101189 ↗ Mar 2010 |
| Target | GHRHR | “Growth hormone-releasing hormone receptor agonist” CHEMBL1237026 ↗ |